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Ranibizumab Monotherapy or Combined with Laser
versus Laser Monotherapy for Diabetic Macular Edema
Paul Mitchell, MD, PhD,1 Francesco Bandello, MD, FEBO,2 Ursula Schmidt-Erfurth, MD,3
Gabriele E. Lang, MD,4 Pascale Massin, MD, PhD,5 Reinier O. Schlingemann, MD, PhD,6
Florian Sutter, MD,7 Christian Simader, MD,8 Gabriela Burian, MD, MPH,9 Ortrud Gerstner, MSc,9
Andreas Weichselberger, PhD,9 on behalf of the RESTORE study group*
Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over
laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic
macular edema (DME).
Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study.
Participants: We included 345 patients aged 18 years, with type 1 or 2 diabetes mellitus and visual
impairment due to DME.
Methods: Patients were randomized to ranibizumab  sham laser (n  116), ranibizumab  laser (n  118),
or sham injections  laser (n  111). Ranibizumab/sham was given for 3 months then pro re nata (PRN);
laser/sham laser was given at baseline then PRN (patients had scheduled monthly visits).
Main Outcome Measures: Mean average change in BCVA from baseline to month 1 through 12 and safety.
Results: Ranibizumab alone and combined with laser were superior to laser monotherapy in improving mean
average change in BCVA letter score from baseline to month 1 through 12 (6.1 and 5.9 vs 0.8; both
P0.0001). At month 12, a significantly greater proportion of patients had a BCVA letter score 15 and BCVA
letter score level 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibi-
zumab  laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was
significantly reduced from baseline with ranibizumab (118.7 m) and ranibizumab  laser (128.3 m) versus
laser (61.3 m; both P0.001). Health-related quality of life, assessed through National Eye Institute Visual
Function Questionnaire (NEI VFQ-25), improved significantly from baseline with ranibizumab alone and combined
with laser (P0.05 for composite score and vision-related subscales) versus laser. Patients received 7 (mean)
ranibizumab/sham injections over 12 months. No endophthalmitis cases occurred. Increased intraocular pres-
sure was reported for 1 patient each in the ranibizumab arms. Ranibizumab monotherapy or combined with laser
was not associated with an increased risk of cardiovascular or cerebrovascular events in this study.
Conclusions: Ranibizumab monotherapy and combined with laser provided superior visual acuity gain over
standard laser in patients with visual impairment due to DME. Visual acuity gains were associated with significant
gains in VFQ-25 scores. At 1 year, no differences were detected between the ranibizumab and ranibizumab 
laser arms. Ranibizumab monotherapy and combined with laser had a safety profile in DME similar to that in
age-related macular degeneration.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
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eDiabetic macular edema (DME) is a leading cause of
visual impairment in patients with diabetic retinopa-
thy.1–3 Focal/grid laser photocoagulation (hereafter re-
ferred to as laser), the current standard of care in DME,
is mostly associated with only vision stabilization. Some
recent trials, however, have demonstrated useful vision
gain with laser; for example, the Diabetic Retinopathy
Clinical Research Network (DRCR.net) study group re-
cently reported a 10-letter gain in 31% patients, whereas
19% of laser-treated patients exhibited progressive visual w
© 2011 by the American Academy of Ophthalmology 
Published by Elsevier Inc. Open access under CC BY-NC-ND license. oss (worsening by 2 lines after 2 years follow-up), at
 risk of developing scotomas.4 –7
Vascular endothelial growth factor (VEGF) levels are
levated in the vitreous of eyes with diabetic retinopathy
aking anti-VEGF treatment an attractive therapeutic mo-
ality in DME.8 Recently, the DRCR.net study group re-
orted that ranibizumab 0.5 mg combined with either
rompt or deferred laser therapy was significantly more
ffective than laser alone in improving vision in patients
ith DME after 1 year of treatment (best-corrected visual
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Ophthalmology Volume 118, Number 4, April 2011acuity [BCVA] letter score of 9 for both ranibizumab
groups vs 3 for laser; P0.001).9 The RESOLVE study
(phase II randomized multicenter) demonstrated that ranibi-
zumab monotherapy was well-tolerated and significantly
more effective than sham treatment (with rescue laser) in
providing rapid and continuous improvements in BCVA
over 12 months (mean BCVA letter score change from
baseline to month 12, 10.3 for ranibizumab vs 1.4 for
sham; P0.0001).10
Apart from Ranibizumab for Edema of the mAcula in
Diabetes study (READ-2),11 there have been no other ran-
domized controlled trials that have assessed the efficacy and
safety of ranibizumab monotherapy compared with laser
monotherapy. Additionally, it is not yet established whether
ranibizumab monotherapy is superior or at least equivalent
to combined therapy. The 12-month, phase III, randomized,
double-masked, multicenter, laser-controlled RESTORE
study was designed to assess whether ranibizumab mono-
therapy or combined with laser was superior to laser alone
in patients with visual impairment due to DME. In addition,
RESTORE is the first study to assess the impact of ranibi-
zumab treatment on health-related quality of life (HRQoL)
outcomes in patients with DME.
Materials and Methods
Study Design
The RESTORE study was a 12-month, double-masked, multi-
center, laser-controlled, phase III study where 345 eligible patients
from 73 centers (10 European countries, Turkey, Canada, and
Australia) were randomized 1:1:1 to 1 of the 3 treatment arms:
Intravitreal ranibizumab (0.5 mg) injection  sham laser, adjunc-
Table 1. Key Baseline Demographic an
Variable
Ranibizu
(n
Mean age  SD (years) 62
Gender, n (% )
Men 7
Women 4
Diabetes type, n (%)
Type I 1
Type II 10
Not stated
Mean time since first diagnosis of diabetes  SD (years) 15.2
Mean time since first diagnosis of DME  SD (years) 1.8
DME type, n (%)*
Focal 6
Diffuse 4
Missing
Mean VA  SD (letter score) 64
Patients with VA letter score 73, n (%) 2
Mean CRT  SD (m) 426
CRT  central retinal thickness; DME  diabetic macular edema; SD 
*Focal DME: More than 67% of leakage originated from leaking microane
whole edema area, but 67% of the leakage originated from MAs in the
Diffuse DME: Less than 33% of leakage originated from leaking MAs the re
comes from MAs, but 33% of the leakage originated from MAs in the centr
616ive administration of intravitreal ranibizumab (0.5 mg) injec-
ion  active laser, or laser treatment  sham injections for 12
onths (for details of randomization and masking, see Appendix
, available online at http://aaojournal.org). One eye was selected
nd treated as the study eye. If both eyes were eligible, the eye
ith the worse visual acuity (VA; assessed at visit 1) was selected
or treatment, unless, based on medical reasons, the investigator
eemed the other eye more appropriate to receive study treatment.
he study was conducted in accordance with the Declaration of
elsinki and International Conference on Harmonization Good
linical Practice guidelines. Approval was obtained from the eth-
cs committee or institutional review board at each contributing
enter. Patients provided written informed consent before entering
he study. The study is registered with clinicaltrials.gov as
CT00687804.
Patients. The study population consisted of 345 male and
emale patients 18 years of age with either type 1 or 2 diabetes
ellitus (as per American Diabetes Association or World Health
rganization guidelines), glycosylated hemoglobin (HbA1c)
10%, and visual impairment due to DME. The key inclusion
riteria were (1) stable medication for the management of diabetes
ithin 3 months before randomization and expected to remain
table during the study; (2) visual impairment due to focal or
iffuse DME (definition in Table 1) in at least 1 eye that was
ligible for laser treatment in the opinion of the investigator; (3)
CVA letter score between 78 and 39, both inclusive, based on
arly Treatment Diabetic Retinopathy Study (ETDRS)-like VA
esting charts administered at a starting distance of 4 meters
approximate Snellen equivalent 20/32–20/160); and (4) decreased
ision due to DME and not other causes, in the investigator’s
pinion (at visit 1). The key exclusion criteria were (1) concomi-
ant conditions in the study eye that could prevent the improve-
ent in VA on the study treatment in the investigator’s opinion;
2) active intraocular inflammation or infection in either eye; (3)
ncontrolled glaucoma in either eye (e.g., intraocular pressure
IOP]  24 mmHg on medication, or from the investigator’s
ease Characteristics (Randomized Set)
0.5 mg
6)
Ranibizumab 0.5 mg  Laser
(n  118) Laser (n  111)
29 64.08.15 63.58.81
9) 70 (59.3) 58 (52.3)
1) 48 (40.7) 53 (47.7)
2) 15 (12.7) 13 (11.7)
8) 102 (86.4) 97 (87.4)
1 (0.8) 1 (0.9)
91 14.629.84 12.939.02
98 1.993.14 1.581.96
2) 68 (57.6) 53 (47.7)
8) 46 (39.0) 52 (46.8)
) 4 (3.4) 6 (5.4)
.11 63.49.99 62.411.11
8) 19 (16.1) 17 (15.3)
8.01 416.4119.91 412.4123.95
dard deviation; VA  visual acuity.
s (MAs) in the whole edema area or 30%–67% leakage from MAs in the
ral subfield.
diffuse leaking capillaries in the whole edema area or 30%–67% leakaged Dis
mab
 11
.99.
3 (62.
3 (37.
3 (11.
3 (88.
0
39.
01.
4 (55.
5 (38.
7 (6.0
.810
3 (19.
.611
stan
urysm
cent
st fromal subfield.
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Mitchell et al  Ranibizumab or Combined With Laser vs Laser for DMEjudgment); (4) panretinal laser photocoagulation (within 6 months)
or focal/grid laser photocoagulation (within 3 months) before
study entry; (5) treatment with antiangiogenic drugs in the study
eye within 3 months before randomization; (6) history of stroke;
and (7) systolic blood pressure (BP) 160 mmHg or diastolic BP
100 mmHg, untreated hypertension, or change in antihyperten-
sive treatment within 3 months preceding baseline.
Study Objectives. The primary objective of this study was to
demonstrate superiority of ranibizumab 0.5 mg as monotherapy or
combined with laser therapy over laser alone (the current standard
of care) with respect to mean average change in BCVA from
baseline over 12 months. Secondary objectives were to evaluate
(1) if ranibizumab 0.5 mg as monotherapy or adjunctive to laser
was superior to laser alone in the proportion of patients with VA
improvement and with BCVA letter score 73 (20/40 Snellen
equivalent) at month 12; (2) the time course of mean change in
BCVA letter score and central retinal (subfield) thickness (CRT);
(3) patient-reported outcomes relative to those associated with
laser treatment; and (4) the safety of intravitreal injections of
ranibizumab 0.5 mg, as monotherapy or adjunctive to laser therapy
relative to laser treatment.
Efficacy and Safety Assessments
Best-Corrected Visual Acuity. We assessed BCVA at every
study visit using ETDRS charts at a starting distance of 4 meters.
The primary efficacy end point was the mean average change in
BCVA letter score from baseline to month 1 through month 12.
Secondary efficacy end points included the mean BCVA letter
score change from baseline to month 12 and proportion of patients
who gained 10 and 15 letters in BCVA and patients with
BCVA letter score 73 at month 12. Mean average change in
BCVA from baseline to month 1 through month 12 was chosen as
the primary efficacy end point as it accounts for both interpatient
and intramonth variability in BCVA and thus gives a more robust
estimate of the VA gained by patients over time compared with the
mean change of BCVA from baseline to study end.
A subgroup analysis of the primary end point was performed on
the basis of demographic and baseline disease characteristics. The
key categories assessed were as follows: DME type (focal/diffuse),
BCVA letter score (60, 61–73, and 73), diabetes type (type
1/type 2), focal and/or grid laser pretreatment (yes/no), CRT
(300, 300–400, and 400 m), ETDRS retinopathy severity
score (10–35, 43 or 47, and 53–85), macular ischemia (yes/no;
measured by the presence of capillary loss on fluorescein angiog-
raphy according to a modified ETDRS grading scale in the center
subfield of 1000 m diameter, where the capillary loss grades
“moderate,” “severe,” or “completely destroyed” were categorized
as “yes” ischemia, and the grades “none” or “mild” were classified
as “no” ischemia).
Optical Coherence Tomography. Optical coherence tomogra-
phy (OCT) was performed at every study visit using Stratus OCT
(Carl Zeiss, Meditec, Dublin, CA). The images were reviewed by
a central reading center to ensure a standardized evaluation. Ret-
inal thickness was determined using individual A-scans along with
each of 6 B-scans. End points included mean change in CRT
(defined from the central macular area 1000 m in diameter) over
time and the proportion of patients with CRT 275 m.
Stereoscopic Color Fundus Photography and Fluorescein
Angiography. Stereoscopic color fundus photography and fluo-
rescein angiography were performed at baseline, month 6, and
month 12. After pupil dilation and before fluorescein dye injection,
red-free and ETDRS 7-field color photographic images of the
retina of the study eye were taken. Anatomic end points included
the proportion of patients with resolution of leakage and cysts at
month 12 as assessed by the central reading center and the pro- lortion of patients with a 3-step change in the ETDRS severity
core from baseline to month 12 (exploratory end point).
Health-Related Quality of Life. We assessed HRQoL using
he visual-specific National Eye Institute Visual Function Ques-
ionnaire (NEI VFQ-25), as well as generic health assessment
tility tools EuroQoL (EQ-5D), and time trade off (TTO). All
uestionnaires were scored by patients at baseline and month 12.
dditionally, the NEI VFQ-25 was scored at month 3 and the
Q-5D was scored at months 3 and 6. End points included the
bsolute change in scores, changes in scores over time, and dif-
erences in scores between treatment groups.
Drug Exposure. The number of ranibizumab/sham injections
nd active/sham laser treatments, and the mean duration of
reatment-free intervals (ranibizumab/sham injection, active/sham
aser) were evaluated over the 12-month assessment period for
ach of the treatment arms.
Safety Assessments. Safety was assessed by the 12-month
ncidence of adverse events (AEs) and serious AEs (SAEs), by
phthalmic examinations and IOP measurements, and by changes
n vital signs and laboratory parameters over the 12-month assess-
ent period.
reatment
anibizumab/Sham Treatment. Patients received 3 initial con-
ecutive monthly injections of ranibizumab (months 0–2; treat-
ent initiation phase), followed by further treatment according to
rotocol-defined retreatment criteria between and including
onths 3 and 11 (continuous/resumed treatment phase; Figure 1,
vailable online at http://aaojournal.org). Intravitreal ranibizumab
njections were performed by the investigators’ usual routines;
oth pre- and postinjection topical antibiotics were used. Sham
anibizumab injection involved imitation of an injection procedure
sing an injection syringe without needle, by applying pressure
gainst the globe.
Retreatment Criteria During Continuous/Resumed Treat-
ent Phase. As of month 3, the protocol required that 1 injection
er month was to be continued if stable VA was not reached.
reatment was suspended if either of the following criteria were
et: (1) if the investigator’s opinion was that no (further) BCVA
mprovement was attributable to treatment with intravitreal injec-
ion at the last 2 consecutive visits, or (2) BCVA letter score  84
approximate Snellen equivalent 20/20) was observed at the last 2
onsecutive visits. After suspension, injections were resumed pro
e nata (PRN [as required]) if there was a decrease in BCVA due
o DME progression, confirmed by clinical evaluation and/or OCT
r other anatomic and clinical assessments, in the opinion of the
nvestigator. Patients were treated at monthly intervals until stable
A was reached again. Thus, reinitiation of intravitreal injections
ncompassed 2 successive monthly treatments.
Laser/Sham Laser Treatment. The first laser treatment (active
r sham depending on treatment group; the ranibizumab  sham
aser group did not receive active laser treatment) was adminis-
ered on day 1. If required, the first laser administration could be
plit into 2 sessions, 4 weeks apart. Retreatments were given in
ccordance with ETDRS guidelines at intervals no shorter than 3
onths from the previous treatment if deemed necessary by the
valuating investigator. Patients receiving retreatment with active
r sham laser continued to be treated with monthly ranibizumab or
ham injections as long as the treatment criteria for intravitreal
njection were fulfilled. Decisions on retreatment with laser/sham
ere independent of decisions to administer ranibizumab/sham
njections and vice versa. Sham laser was applied under the same
rocedure used for laser treatment but without switching on the
aser beam, and by imitating depression of the laser pedal.
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The primary analysis was performed on the full analysis set (FAS),
consisting of all patients who received 1 application of the study
treatment ([sham] injection and/or [sham] laser) and had 1
postbaseline assessment for BCVA. The primary end point was the
difference between the average BCVA letter score over all
monthly postbaseline assessments from month 1 to month 12 and
the baseline BCVA letter score ( average change from baseline).
The analysis of the primary end point used the last observation
carried forward approach for the imputation of missing data.
Sensitivity analyses of the primary end point were performed using
(1) an “as documented” approach in the FAS where the average
change from baseline in BCVA was calculated from observed
changes only, and (2) a per-protocol set with missing data being
handled in the same way as for the FAS.
A sample size of 105 randomized patients per treatment group
was considered to have 90% power to detect a 5-letter BCVA
score treatment difference in the mean average change in BCVA
compared with baseline from month 1 through month 12, assuming
a standard deviation (SD) of 10 BCVA letter score with a Bon-
ferroni adjusted 1-sided alpha level of 0.0125 for the 2 compari-
sons. Hypothesis testing of the superiority of ranibizumab mono
and/or ranibizumab/laser combination compared with laser was
done in parallel according to the Hochberg procedure controlling
the overall 1-sided alpha level at 0.025. The statistical hypothesis
testing of the average change from baseline in BCVA was based
on the stratified Cochran–Mantel–Haenszel test using the observed
values as scores and with stratifications according to DME type
(focal, diffuse) and baseline BCVA letter score (60, 61–73,
73). Two-sided 95% confidence intervals for the mean average
changes in BCVA and for the corresponding pair-wise difference
between treatments, were calculated using the least-square means
from an analysis of variance model with treatment, DME type, and
baseline BCVA category (see above) as factors.
The safety analysis was conducted on the safety set that com-
prised all patients who received 1 application of study treatment
and had 1 postbaseline safety assessment.
Results
Patient Disposition and Demographics
A total of 345 patients were randomized to receive ranibizumab
0.5 mg (n  116), ranibizumab 0.5 mg  laser (n  118), or laser
(n  111). The efficacy analysis was performed on the FAS that
comprised 115 (ranibizumab 0.5 mg), 118 (ranibizumab  laser),
and 110 (laser) patients (1 patient each from the ranibizumab and
laser arm were excluded because they had no postbaseline VA
data). The safety analysis was conducted on the safety set com-
prising 115 (ranibizumab), 120 (ranibizumab  laser), and 110
(laser) patients. Three patients (1 in each treatment arm) received
active ranibizumab and active laser in the study eye at baseline
without consideration of the randomization, and all 3 of these were
analyzed under the ranibizumab laser arm for the safety set. The
patient disposition was comparable across the 3 treatment groups
(Fig 2, available online at http://aaojournal.org); 87.9% (ranibi-
zumab), 87.3% (ranibizumab  laser), and 88.3% (laser) of the
patients completed the 12-month study period. There were 2 deaths
in each of the 3 treatment arms. Baseline demographics and
diabetes characteristics were comparable across the 3 treatment
arms (Table 1). [
618fficacy
est-Corrected Visual Acuity. The mean average change  SD
n the BCVA letter score from baseline to month 1 through month
2 was significantly superior with ranibizumab (6.1  6.4;
0.0001) and ranibizumab  laser (5.9  7.9; P0.0001) than
ith laser treatment (0.8  8.6), hence the primary end point was
chieved (Fig 3; Table 2). There was no difference detected
etween the 2 ranibizumab treatment arms (P  0.61, Cochran–
antel–Haenszel test). Similar results were obtained (data not
hown) for the primary end point using the “as documented”
pproach and the per protocol set. The last observation carried
orward calculation of the average level of BCVA letter score over
ll monthly post-baseline assessments from month 1 to month 12
as based on 92.6% (ranibizumab), 92.9% (ranibizumab  laser),
nd 91.4% (laser) observed monthly BCVA assessments.
The mean change  SD in BCVA letter score from baseline to
onth 12 was 6.8  8.3 (P0.0001) in the ranibizumab arm, 6.4 
1.8 (P  0.0004) in the ranibizumab  laser arm, and 0.9  11.4
n the laser arm (Table 2). In the ranibizumab and ranibizumab 
aser arms, a rapid and clinically relevant improvement in mean
CVA was observed as of the first assessment posttreatment (at
onth 1), which continued up to month 3 and was sustained at
he month 3 level until the last assessment time point at month
2. In the laser arm, mean BCVA stabilized around baseline
evel and reached a 0.9 letter gain at month 12 (Fig 4A).
At month 12, 53.0% (vs 19.8% at baseline) of patients in the ranibi-
umab arm and 44.9% (vs 16.1% at baseline) of patients in the ranibi-
umab  laser arm had a BCVA letter score 73 (20/40 Snellen
quivalent) compared with 23.6% (vs 15.3% at baseline) of patients in the
aser arm (estimated treatment difference vs laser, 29.4% [95% confi-
ence interval, 17.3–41.5] for ranibizumab and 21.3% [95% confidence
nterval, 9.3–33.3] for ranibizumab laser; Table 2; month 3 and 6 data
n Table 3, available online at http://aaojournal.org).
A significantly greater proportion of patients gained5 BCVA
etters with ranibizumab (65.2% [ranibizumab] and 63.6% [ranibi-
umab  laser]; P0.0001) versus laser alone (33.6%). Similarly,
significantly greater proportion of patients in either the ranibi-
umab arm or the ranibizumab  laser arm compared with the
aser arm gained a 10 BCVA letter score (37.4% and 43.2% vs
5.5%; P0.0001 for both) and a 15 BCVA letter score (22.6%
igure 3. Mean average change in best-corrected visual acuity (BCVA)
etter score from baseline to months 1 through 12 (primary end point).
E  standard error.P  0.0005] and 22.9% [P  0.0037] vs 8.2%; Table 2). Con-
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Mitchell et al  Ranibizumab or Combined With Laser vs Laser for DMEversely, a lower proportion of patients lost 10 and 15 letters in
both the ranibizumab arms compared with the laser arm.
The mean average BCVA change from baseline to month 1 through
month 12 by some of the key subgroups including patients with/without
macular ischemia and those with focal/diffuse DME are presented in
Figure 5A–E (Fig 5C–E and Fig 6 [mean average change in BCVA],
available online at http://aaojournal.org). Each of the ranibizumab patient
subgroups did better on average than those on laser alone in terms of the
primary efficacy end point (all categories presented in Table 4 available
online at http://aaojournal.org).
Central Retinal Thickness. The mean CRT change from
baseline to month 12 decreased significantly for ranibizumab
(118.7 m; P  0.0002) and ranibizumab  laser (128.3 m;
P0.0001) compared with laser (61.3 m; Fig 4B; Table 2).
At month 12, the proportion of patients with CRT  275 m
was significantly greater in the ranibizumab monotherapy arm
(49.1%; P  0.0408) and the ranibizumab  laser arm (55.1%;
P  0.0075) compared with the laser arm (39.1%).
Colour Fundus Photography and Fluorescein
Angiography
At month 12, a significantly larger proportion of patients had
Table 2. Best-Corrected Visual Acuity (BCVA) and Central R
Last Observatio
Ran
Mean average change in BCVA letter score from baseline to
month 1–12 (primary end point)*
Mean  SD
Median (range) 6.1
95% CI for mean**
Comparison verus laser
Difference in LS means (vs laser)†
95% CI for difference†
P value‡
Proportion of patients with BCVA letter score 73 at month 12
n (%)
95% CI for percentage
Difference in percentage (vs laser)
95% CI for difference
P value‡
Categorized BCVA letter score outcome at month 12, n (%)
Gain of 5 75
Gain of 10§ 43
Loss of 10 4
Gain of 15§ 26
Loss of 15 1
Mean CRT change from baseline to month 12, m
Mean  SD 
Median (range) 
95% CI for mean**
Comparison verus laser
Difference in LS means (vs laser)†
95% CI for difference†
P value‡
ANOVA  analysis of variance; CI  confidence intervals; LS  least s
*Missing VA values imputed using last observation carried forward for 7.
**Two-sided 95% CI are based on the t-distribution.
†Differences in LS means and the 2-sided 95% CIs are estimated from pa
‡P-values for treatment difference are from the 2-sided stratified Cochran
§Specified gain, or BCVA letter score of 84.resolution of leakage in the ranibizumab (19.4%; P  0.0002) and 1he ranibizumab laser (13.7%; P 0.0114) arms compared with
he laser arm (2.2%).
ealth-Related Quality of Life
isual Functioning Questionnaire. The mean changes in the NEI
FQ-25 composite scores by treatment arms at months 3 and 12
re presented in Figure 7A (available at online http://aaojournal.
rg). For both ranibizumab arms the composite scores increased
rom month 3 to 12, whereas it decreased for the laser arm. At
onth 12, there was a greater improvement in the composite
cores in the ranibizumab (5.0; P  0.014) and ranibizumab 
aser (5.4; P 0.004) arms compared with the laser arm. At month
2, greater differences from baseline in NEI VFQ-25 subscale
cores (general vision, near activities, and distance activities) were
bserved for ranibizumab and ranibizumab  laser versus laser
lone (all P0.05; Fig 7B–D).
At month 12, excellent to good eyesight was reported by 46%
nd 50% of the patients in the ranibizumab and ranibizumab 
aser arm compared with 21% and 23% of the patients at baseline
determined by the individual NEI VFQ-25 question pertaining to
atient’s perception of eyesight posttreatment). Excellent to good
ision was reported by only 24% patients with laser alone at month
l Thickness (CRT) Outcome at Month 12 (Full Analysis Set,
rried Forward)
mab 0.5 mg
115)
Ranibizumab 0.5 mg 
Laser (n  118)
Laser
(n  110)
6.43 5.97.92 0.88.56
.9–25.2) 6.0 (26.7–27.6) 1.3 (37.8–26.8)
7.3) (4.4, 7.3) (0.8, 2.4)
5.4 4.9
7.4) (2.8, 7.0)
.0001 0.0001
(53.0) 53 (44.9) 26 (23.6)
, 62.4) (35.7, 54.3) (16.1, 32.7)
9.4 21.3
, 41.5) (9.3, 33.3)
.0001 0.0002
) 75 (63.6) 37 (33.6)
) 51 (43.2) 17 (15.5)
5 (4.2) 14 (12.7)
) 27 (22.9) 9 (8.2)
4 (3.4) 9 (8.2)
7115.07 128.3114.34 61.3132.29
0 (514–120) 116.5 (487–103) 60.0 (451–329)
0.1, 97.3) (149.3, 107.3) (86.5, 36.1)
61.5 70.6
.8, 29.2) (102.1, 39.0)
0.0002 0.0001
; SD  standard deviation.
(ranibizumab), 7.06% (ranibizumab  laser) and 8.56% (laser) patients.
e ANOVA (stratified) model.
tel-Haenszel test using the row means score.etina
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Ophthalmology Volume 118, Number 4, April 2011EQ-5D Scores. None of the differences from baseline in the
mean EQ-5D visual analog scores between the ranibizumab treat-
ment groups and laser alone were statistically significant at any
time point (Fig 8, available online at http://aaojournal.org).
TTO Scores. Patients were asked what proportion of their life
expectancy they would be willing to trade off to avoid their current vision
Figure 4. A, Mean change in best-corrected visual acuity (BCVA) letter
(CRT) from baseline to month 12. SE  standard error.
Figure 5. Mean change in best-corrected visual acuity (BCVA) from bas
acuity and (B) central retinal thickness. BCVA  best-corrected visual acuity
620mpaired health state, the resulting proportion representing the utility of
heir current health state. An improvement of 0.13 in the utility score was
bserved for ranibizumab monotherapy (baseline score 0.69), 0.032 for
anibizumab  laser (baseline score 0.73), and 0.023 for laser alone
baseline score 0.73; Fig 9, available online at http://aaojournal.org); these
ifferences were not significant versus laser.
from baseline to month 12. B, Mean change in central retinal thickness
over 12 months by key baseline characteristics, (A) best-corrected visualscoreeline
; CRT  central retinal thickness; SE  standard error.
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Mitchell et al  Ranibizumab or Combined With Laser vs Laser for DMEDrug Exposure
Ranibizumab Injections. The mean number of ranibizumab/sham
injections received was similar for all treatment groups (6.8–7.3
injections; Table 5). Between months 3 and 11, patients received
an average of 4.1 ranibizumab intravitreal injections in the ranibi-
zumab arm, 3.8 in the ranibizumab  laser arm, and 4.5 sham
injections in the laser-treated arm.
Treatment-Free Interval for Ranibizumab or Sham Injec-
tions. A greater proportion of patients in the ranibizumab (85.2%)
and ranibizumab laser arms (81.7%) had their dose interrupted due
to disease improvement compared with the laser arm (68.2%), which
received sham injections only (Table 6 available online at http://
aaojournal.org). According to the protocol, the first possible time
point to stop injections (ranibizumab or sham) because of stability was
month 3. At month 3, more patients in the ranibizumab arms (32.2%
[ranibizumab] and 30.8% [ranibizumab  laser]) than the laser arm
(20.9%) were not treated because of stability of VA.
After treatment interruption, the mean duration of the treatment-free
interval was approximately 2 months in both the ranibizumab and
the laser arms and approximately 2.5 months in the ranibizumab
laser arm (Table 7 available online at http://aaojournal.org). Fewer
patients received monthly treatment in the ranibizumab (8.0%) and
ranibizumab  laser (7.6%) arms compared with the laser arm
(17.8%). The proportion of patients with a maximum treatment-
free interval of 3 months was similar across treatment arms
(57.9%–61.9%).
Laser Treatment. The mean number of active/sham laser
treatments was similar for all treatment groups (1.7–2.1 adminis-
trations; Table 8 available online at http://aaojournal.org). From
month 3 to month 11, patients received 0.9 sham laser adminis-
trations in the ranibizumab arm, 0.7 active laser administrations in
the ranibizumab  laser arm, and 1.1 in the laser-treated arm
(Table 8, available online at http://aaojournal.org). During this
period, 49.6% (ranibizumab) and 44.5% (ranibizumab  laser) of
the patients received a sham/active laser treatment compared with
63.9% patients in the laser arm.
Safety
Serious Adverse Events. No ocular SAEs were reported in the
ranibizumab arm, whereas there were 2 cases each reported in the
ranibizumab  laser (cataract) and laser only (cataract and macu-
lopathy) arms; none suspected to be related to study drug or
procedure (Table 9 available online at http://aaojournal.org). There
were no cases of endophthalmitis reported in any of the treatment
arms (7 ranibizumab or sham injections over the 12-month
Table 5. Number of Ranibizumab/
Ranibizumab 0.
(n  115)
Total number of injections Ranibizuma
Total 800
Mean  SD 7.02.81
Median (Range) 7.0 (1–12)
Distribution of injections, n (%)
1–3 16 (13.9)
4–6 37 (32.2)
7–9 40 (34.8)
10–12 22 (19.1)
SD  standard deviation.treatment period). There were 23 (20%) patients with nonocular iAEs in the ranibizumab arm, 17 (14.2%) in the ranibizumab 
aser arm, and 15 (13.6%) in the laser arm (Table 9, available
nline at http://aaojournal.org). The nonocular SAEs that were
uspected by the investigator to be related to a study drug or
rocedure included intestinal obstruction (0.9%), hypoglycemia
0.9%), pulmonary embolism (1.7%), dyspnea (0.9%), and arterial
hrombosis limb (0.9%) in the ranibizumab arm, coronary artery
cclusion (0.8%) in the ranibizumab  laser arm. There were 6
eaths reported during the study (2 per treatment arm), none of
hich were considered to be related to the study drug by the
nvestigator (Table 9, available online at http://aaojournal.org).
Adverse Events. The most frequently occurring ocular and
onocular AEs are summarized in Table 10 (available online at
ttp://aaojournal.org). The most common ocular AE was eye pain
n all 3 treatment arms. Eye pain was also the most common ocular
E suspected to be related to study drug (10–12 cases) followed
y conjunctival hemorrhage, which was reported in the ranibi-
umab arms only (8–9 cases). One patient each in the ranibizumab
rms experienced IOP increase, which was suspected to be related
o study drug or procedure (Table 11 available online at http://
aojournal.org). Nasopharyngitis was the most common nonocular
E observed in all 3 treatment arms. Some of the nonocular AEs
hat were suspected to be related to study drug or procedure
ncluded pulmonary embolism (n  2), limb arterial thrombosis
n  1), arthralgia (n  1), and hypertension (n  1), all in the
anibizumab arm, coronary artery occlusion (n  1) in the ranibi-
umab  laser arm, and hypertension (n  1) in the sham arm
Table 11). Hypertension, the most common AE potentially related
o systemic VEGF inhibition, was comparable in all treatment
rms (Table 12). Arterial thromboembolic events were reported by
patients in the ranibizumab arm and 1 patient each in the
anibizumab  laser and laser arms. These included 1 case each of
yocardial infarction in the ranibizumab and ranibizumab  laser
rm, and 1 case of cerebrovascular accident in the ranibizumab arm.
t the end of the study, there was no clinically significant differ-
nce between treatment arms for either mean BP or IOP, and the
alues of clinical laboratory evaluations were similar among the
tudy arms (details in Appendix 3, available online at http://
aojournal.org).
iscussion
he results from the RESTORE study demonstrate that
reatment with ranibizumab as monotherapy and combined
ith laser treatment is superior to laser treatment in rapidly
Injections Received (Safety Set)
Ranibizumab 0.5 mg  Laser
(n  120)
Laser
(n  110)
Ranibizumab Sham
816 802
6.82.95 7.33.22
7.0 (2–12) 7.0 (1–12)
23 (19.2) 19 (17.3)
34 (28.3) 32 (29.1)
35 (29.2) 22 (20.0)
28 (23.3) 37 (33.6)Sham
5 mg
bmproving and sustaining VA in patients with visual im-
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Ophthalmology Volume 118, Number 4, April 2011pairment due to DME. There were no efficacy differences
detected between the ranibizumab and ranibizumab com-
bined with laser treatment arms. A greater proportion of
patients treated with ranibizumab gained5,10, and15
BCVA letter scores from baseline compared with the laser-
treated patients.
Ranibizumab treatment consistently demonstrated signif-
icant and superior VA benefit in all subgroups of DME
patients, including patients with focal or diffuse DME and
those with or without prior laser as compared with laser
treatment alone. The functional improvements in BCVA
were accompanied by significant improvements in anatomic
end points, CRT on OCT, and resolution of leakage on
fluorescein angiography. At month 12, 49.1% (ranibi-
zumab), 55.1% (ranibizumab  laser), and 39.1% (laser)
patients had CRT 275 m, whereas 50.9%, 44.9%, and
60.9%, respectively, had CRT 275 m.
The efficacy results with ranibizumab treatment from the
RESTORE study are consistent with the recently published
DRCR.net and RESOLVE studies.9,10 Results from the
DRCR.net study showed that ranibizumab used in conjunc-
tion with laser therapy (prompt or deferred) was signifi-
cantly more effective than laser alone in improving VA in
patients with DME after 1 year of treatment (9 [both] vs
3 BCVA letter score; P0.001).9 In the DRCR.net study,
approximately 30% of the ranibizumab  laser patients
gained a 15 BCVA letter score from baseline compared
with 15% of the laser-treated patients.
The RESOLVE study demonstrated that ranibizumab
provided rapid and continuous improvements in BCVA
compared with sham over a period of 12 months (mean
average change in BCVA letter score from baseline to
month 12, 7.8 for ranibizumab vs 0.1 for sham;
P0.0001).10 At month 12, approximately 32% of the
ranibizumab-treated patients gained a 15 BCVA letter
score compared with 10% in the sham control arm.
The observed numerical differences in the BCVA out-
come between RESTORE and RESOLVE may be partly
attributed to the differences in eligibility criteria and as a
consequence to baseline characteristics of the enrolled pa-
tients. Additionally, the 2 studies had different retreatment
criteria, which led to an average of 10 ranibizumab injec-
tions in the RESOLVE study and 7 injections in the
Table 12. Adverse Events Potentially Related
Inhibition
Preferred Term, n (%)
Ranibizumab 0.5
N  115
Total 14 (12.2)
Arterial thromboembolic events 6 (5.2)
Angina pectoris 2 (1.7)
Pulmonary embolism 2 (1.7)
Cerebrovascular accident 1 (0.9)
Myocardial infarction 1 (0.9)
Hypertension 9 (7.8)
Non-ocular hemorrhage 1 (0.9)
Epistaxis 1 (0.9)
Proteinuria 1 (0.9)RESTORE study. t
622Visual impairment or reduced VA adversely impacts pa-
ients’ independence (activities like reading, interacting so-
ially, watching TV, driving, etc) and HRQoL.12–14 The
ESTORE trial is the first to assess the impact of ranibizumab
reatment on HRQoL, particularly using the NEI VFQ-25
uestionnaire. Ranibizumab showed progressive and sustained
mprovements in HRQoL as assessed by the NEI VFQ25
omposite scores. The mean change in VFQ-25 composite
cores was significant, with ranibizumab monotherapy and
ombined with laser (5.0 and 5.4 point) versus laser. These
esults are consistent with those reported for ranibizumab in the
eovascular AMD studies Anti-VEGF Antibody for the Treat-
ent of Predominantly Classic Choroidal Neovascularization
n Age-Related Macular Degeneration (ANCHOR) and Min-
mally Classic/Occult Trial of the Anti-VEGF Antibody
anibizumab in the Treatment of Neovascular Age-Related
acular Degeneration (MARINA), where a 4- to 6-point im-
rovement in mean NEI VFQ-25 scores represented a clini-
ally meaningful change corresponding with a 15-letter im-
rovement in BCVA.15 The strongest evidence of HRQoL
enefit for ranibizumab compared with laser alone was ob-
erved for general vision, near, and distance activities NEI
FQ-25 subscales. Adding to the HRQoL outcomes are the
ata on the proportion of patients who had a BCVA letter score
73 (20/40 Snellen equivalent, the legal minimum for driving in
he United States and the United Kingdom) in the study eye at
onth 12. In RESTORE, at month 12, 44.9% (ranibizumab 
aser) and 53.0% (ranibizumab) patients had a BCVA letter
core 73 versus 16.1% and 19.8% patients at baseline,
hereas with laser 23.6% patients had a BCVA letter score
73 versus 15.3% at baseline. For the EQ-5D scores, none
f the differences between the ranibizumab treatment arms
nd laser arm at any time point were significant. This is not
urprising given that EQ-5D does not contain any vision-
elated domains, and has known ceiling effects,16 so the
cale may lack sensitivity in detecting changes in DME
utcomes.
For the TTO scores, the change in mean utility score of
.13 with ranibizumab was not statistically different from
aser alone at month 12 (P  0.10). Results from the TTO
tility measurement indicate a numerical improvement with
anibizumab vs laser alone, and hence a possible impact on
he quality-adjusted life years associated with ranibizumab
ystemic Vascular Endothelial Growth Factor
fety Set)
Ranibizumab 0.5 mg  Laser
N  120
Laser
N  110
7 (5.8) 11 (10.0)
1 (0.8) 1 (0.9)
0 0
0 1 (0.9)
0 0
1 (0.8) 0
6 (5.0) 9 (8.2)
0 1 (0.9)
0 1 (0.9)
1 (0.8) 0to S
(Sa
mgherapy.
m
c
u
p
s
d
t
e
e
t
b
c
a
i
o
n
R
p
t
2
l
t
w
t
p
e
f
R
(
t
c
s
s
v
s
R
a
m
p
p
t
s
t
z
g
D
p
p
s
v
t
A
R
Mitchell et al  Ranibizumab or Combined With Laser vs Laser for DMEThe RESTORE study used retreatment criteria that were
designed to enable an individualized treatment regimen based
on patients’ disease stability. Patients were assessed monthly to
observe disease stability/activity and to guide treatment inter-
ruption or reinitiation through changes in VA, supported by
clinical and anatomic evaluations attributable to the progres-
sion of DME. The validity of this approach was confirmed by
the efficacy outcome, which showed that the PRN retreatment
regimen could maintain the BCVA gained at the end of the
treatment initiation phase. Furthermore, this was achieved with
an average of 4 injections in the 9-month continuous/resumed
treatment phase. However, it is unknown whether or not VA
gains would have been greater if monthly treatment had been
maintained over 12 months. Ongoing ranibizumab clinical
trials, such as the Ranibizumab Injection in Subjects with
clinically significant macular Edema with center involvement
secondary to diabetes mellitus (RISE, NCT00473330)17 and
the Ranibizumab Injection in subjects with clinically signifi-
cant macular Edema with center involvement secondary to
Diabetes mellitus (RIDE, NCT00473382)18 where monthly
injections are mandated for 24 months will provide data on
maximal VA gains in DME with monthly therapy. Overall, a
greater proportion of patients interrupted treatment due to
disease stability with ranibizumab than laser (85% [ranibi-
zumab] and 82% [ranibizumab  laser] vs 68%), which was
expected because the laser arm received sham injections only.
Approximately 33% of the ranibizumab-treated patients
interrupted treatment for the first time at month 3 due to
treatment efficacy. The proportion of patients with a
maximum treatment-free interval of 3 months was sim-
ilar across treatment arms (57.9%– 61.9%).
The results from the RESTORE study have assessed the
treatment effect of ranibizumab monotherapy in DME, as well
as the potential benefit of combining it with laser therapy. Over
the 1-year study period, the results from RESTORE show that
there were no significant efficacy differences detected between
the ranibizumab and the ranibizumab combined with laser treat-
ment arms with respect to improvements in BCVA, as well
as the number of injections. Overall, the retreatment criteria
based on disease stability used in the RESTORE study
allowed a reduction in the number of injections compared
with the RESOLVE study, through monthly monitoring to
assess patients’ need for retreatment.
Ranibizumab as monotherapy or combined with laser was
well-tolerated in patients with visual impairment due to DME
over 12 months. There were no ocular SAEs observed in the
ranibizumab arm. There were no incidences of glaucoma re-
ported in any of the treatment arms and only 1 patient in each
ranibizumab arm reported increased IOP. Both cases of IOP
increase resolved on their own, without treatment, and the
investigator considered these events to be related to injection
procedure and not to the drug. Ranibizumab treatment was not
found to be associated with an increased risk of cerebrovascu-
lar or cardiovascular events in DME patients over 12 months;
there were no cases of endophthalmitis reported in the study.
The pooled analysis of the 2 pivotal studies, RESOLVE and
RESTORE, resulted in an incidence rate of 1.4% for endoph-
thalmitis at 1 year, which is consistent with the incidence rate
of 1.6% found in the pooled analysis of the pivotal AMD
studies, ANCHOR, MARINA, and PIER (A Phase IIIb,ulticenter, randomized, double-masked, sham Injection-
ontrolled study of the Efficacy and safety of Ranibizumab;
npublished data, July 21, 2008). The incidence of AEs
otentially related to systemic VEGF inhibition (hyperten-
ion, proteinuria, and nonocular hemorrhage) were low and
id not differ compared with the laser control cohort. Fur-
hermore, ranibizumab treatment did not negatively influ-
nce the VA outcome or the progression of macular isch-
mia, as confirmed by assessing the BCVA at month 12 in
he subgroups with or without the presence of ischemia at
aseline, as well as by the degree of capillary loss in the
entral subfield from baseline to month 12 (Appendix 2,
vailable online at http://aaojournal.org). The safety find-
ngs from this study are consistent with the safety profile of
ther studies with ranibizumab treatment in DME9,10 and
eovascular AMD.19,20
In summary, data from the 3 randomized clinical trials
ESOLVE, DRCR.net and RESTORE involving 1000
atients provide robust evidence for the efficacy and
olerability of ranibizumab in DME.9,10 Furthermore, the
4-month results from DRCR.net and the recently pub-
ished READ-2 study have shown that ranibizumab sus-
ains efficacy9,11 through year 2 of treatment and was
ell-tolerated.9 These reports may lead to a shift in
reatment paradigm for DME, from laser, to newer ap-
roaches using ranibizumab. Results from the 2-year
xtension of the RESTORE study will add to the data
rom studies REVEAL (NCT00989989),21 RIDE,18
ISE,17 and RETAIN (NCT01171976),22 and DRCR.net
4-year follow-up) and are expected to further enhance
he evidence for ranibizumab therapy in DME in the
oming years.
In conclusion, RESTORE is the first study to demon-
trate that ranibizumab monotherapy provides significantly
uperior benefit over standard-of-care laser in patients with
isual impairment due to DME, rapidly improving and
ustaining BCVA over the 12-month treatment period.
anibizumab therapy was administered using an individu-
lized PRN regimen with monthly monitoring and retreat-
ent based on disease stability. During the 12-month study
eriod combining laser with ranibizumab did not seem to
rovide any advantage compared with ranibizumab mono-
herapy in terms of improving BCVA and treatment expo-
ure. However, longer follow-up may be required to assess
he benefit of combining laser with ranibizumab. Ranibi-
umab consistently improved BCVA across all the sub-
roups of patients, including patients with focal or diffuse
ME. Ranibizumab treatment was also associated with
rogressive and sustained improvements in HRQoL com-
ared with laser alone, as assessed by the NEI VFQ-25
cores. Ranibizumab was well-tolerated in patients with
isual impairment due to DME with a safety profile similar
o the well-established safety profile in neovascular
MD.19,20
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